Abstracts
Showing 817 abstracts.
IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48
Conference
XIX International AIDS Conference
Study
P1066
Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants.
Conference
XIX International AIDS Conference
Study
P1030
Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093
Conference
XIX International AIDS Conference
Study
P1093
Predictors of Tuberculosis Disease in HIV-infected and HIV-exposed uninfected children from Southern Africa: IMPAACT P 1041 study
Conference
XIX International AIDS Conference
Study
P1041
Association between nevirapine-resistant HIV-variants and antiretroviral treatment outcomes in single-dose nevirapine exposed infants.
Conference
XIX International AIDS Conference
Study
P1060
HIV-1 viral kinetics among in utero and intrapartum infected infants in NICHD HPTN 040/ PACTG 1043.
Conference
XIX International AIDS Conference
Study
P1043/HPTN 040
Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Raltegravir (RAL Pharmacokinetics (PK) and Safety in Neonates (IMPAACT P1097)
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Study
P1097
Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Study
P1026S
Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age
Conference
19th Conference on Retroviruses and Opportunistic Infections
Study
P1066